Compile Data Set for Download or QSAR
maximum 50k data
Found 141 Enz. Inhib. hit(s) with all data for entry = 7160
TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178163(US9120808, Example 41 | US9120808, Example 42)
Affinity DataIC50:  0.200nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178163(US9120808, Example 41 | US9120808, Example 42)
Affinity DataIC50:  0.400nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178167(US9120808, Example 46 | US9120808, Example 47)
Affinity DataIC50:  0.400nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178167(US9120808, Example 46 | US9120808, Example 47)
Affinity DataIC50:  0.5nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178215(US9120808, Example 58)
Affinity DataIC50:  0.600nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178163(US9120808, Example 41 | US9120808, Example 42)
Affinity DataIC50:  0.800nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178215(US9120808, Example 58)
Affinity DataIC50:  1.40nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178167(US9120808, Example 46 | US9120808, Example 47)
Affinity DataIC50:  1.70nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178163(US9120808, Example 41 | US9120808, Example 42)
Affinity DataIC50:  1.70nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178170(US9120808, Example 49)
Affinity DataIC50:  1.80nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178169(US9120808, Example 48)
Affinity DataIC50:  2.40nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178170(US9120808, Example 49)
Affinity DataIC50:  2.60nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178171(US9120808, Example 50)
Affinity DataIC50:  3.20nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178167(US9120808, Example 46 | US9120808, Example 47)
Affinity DataIC50:  3.40nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178165(US9120808, Mixture of Example 43 and Example 44)
Affinity DataIC50:  3.5nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178171(US9120808, Example 50)
Affinity DataIC50:  4.20nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178169(US9120808, Example 48)
Affinity DataIC50:  4.20nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178165(US9120808, Mixture of Example 43 and Example 44)
Affinity DataIC50:  4.30nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178201(US9120808, Example 26)
Affinity DataIC50:  9.20nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178214(US9120808, Example 57)
Affinity DataIC50:  10.6nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178198(US9120808, Example 18)
Affinity DataIC50:  13.9nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM50053173((2S,3S,5R)-3-Methyl-4,4,7-trioxo-3-[1,2,3]triazol-...)
Affinity DataIC50:  17.2nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178203(US9120808, Example 34)
Affinity DataIC50:  21.7nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178214(US9120808, Example 57)
Affinity DataIC50:  22.6nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178198(US9120808, Example 18)
Affinity DataIC50:  27.1nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM50021959(CHEMBL777 | MM 14151 | US9120808, Clavulanic acid ...)
Affinity DataIC50:  29.5nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM50021959(CHEMBL777 | MM 14151 | US9120808, Clavulanic acid ...)
Affinity DataIC50:  30.3nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178200(US9120808, Example 24)
Affinity DataIC50:  30.6nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178201(US9120808, Example 26)
Affinity DataIC50:  36.3nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178204(US9120808, Example 37)
Affinity DataIC50:  44.2nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM60600(US9120808, Example 13)
Affinity DataIC50:  47.7nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178203(US9120808, Example 34)
Affinity DataIC50:  50.3nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178200(US9120808, Example 24)
Affinity DataIC50:  62.2nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178196(US9120808, Example 16)
Affinity DataIC50:  65.2nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178182(US9120808, Example 1)
Affinity DataIC50:  66.6nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178210(US9120808, Example 53)
Affinity DataIC50:  72.8nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178188(US9120808, Example 7)
Affinity DataIC50:  78.4nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178196(US9120808, Example 16)
Affinity DataIC50:  80.5nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBeta-lactamase(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178203(US9120808, Example 34)
Affinity DataIC50:  88.4nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178185(US9120808, Example 4)
Affinity DataIC50:  89nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178211(US9120808, Example 54)
Affinity DataIC50:  97nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178202(US9120808, Example 32)
Affinity DataIC50:  122nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBeta-lactamase(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178165(US9120808, Mixture of Example 43 and Example 44)
Affinity DataIC50:  126nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178191(US9120808, Example 10)
Affinity DataIC50:  140nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178204(US9120808, Example 37)
Affinity DataIC50:  141nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178188(US9120808, Example 7)
Affinity DataIC50:  217nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178210(US9120808, Example 53)
Affinity DataIC50:  219nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM50053173((2S,3S,5R)-3-Methyl-4,4,7-trioxo-3-[1,2,3]triazol-...)
Affinity DataIC50:  222nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
TargetBeta-lactamase TEM(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178209(US9120808, Example 51)
Affinity DataIC50:  254nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBeta-lactamase(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178163(US9120808, Example 41 | US9120808, Example 42)
Affinity DataIC50:  285nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In DepthDetails US Patent
Displayed 1 to 50 (of 141 total ) | Next | Last >>
Jump to: